iRhythm Technologies Inc IRTC 深 滬
已收盤 07-18 16:00:00 美东时间
136.24
+0.480
+0.35%
華盛通- 最 高138.41
- 今 開137.26
- 成交量 43.39万股
- 最 低 135.72
- 昨 收 135.76
- 總市值 43.50亿
- 52周最高 157.13
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 55.92
- 委 比 -60.08%
- 總股本 3192.53万
- 歷史最高 286.19
- 量 比 1.03
- 振 幅 1.98%
- 歷史最低 22.25
- 每 手 1
- 風險率 17.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多iRhythm Technologies to Report Second Quarter 2025 Financial Results on July 31, 2025
iRhythm Technologies, Inc. (NASDAQ:IRTC) announced it will release its second quarter 2025 financial results after market close on July 31, 2025. The company’s management will host a conference call at 4:30 p.m. ET that day. The call can be accessed via the company’s investor website.
07-17 20:30
Morgan Stanley Maintains Overweight on iRhythm Technologies, Lowers Price Target to $147
Morgan Stanley analyst Cecilia Furlong maintains iRhythm Technologies (NASDAQ:IRTC) with a Overweight and lowers the price target from $160 to $147.
07-15 21:09
iRhythm Technologies Announces Board Member Retirements and New Director Appointments
<p>iRhythm Technologies, Inc. announced that board members Mark Rubash and Ralph Snyderman, M.D., are retiring, effective July 7, 2025. They are being replaced by Karen McGinnis and Kevin O’Boyle, who bring extensive financial and industry experience to the board. Rubash, who joined in 2016, contributed decades of finance and strategy expertise, while Snyderman, since 2017, provided clinical insight during the company's early challenges. Both ret...
07-07 12:30
New Data Presented at ADA 2025 Highlights Burden and Risk Associations of Cardiac Arrhythmias in Patients with Type 2 Diabetes and Chronic Kidney Disease
Retrospective analyses demonstrate cardiac arrhythmias are common and occur early in type 2 diabetes patients, often preceding major cardiovascular events. Studies suggest early detection strategies are critical for at-risk populations.
06-23 12:30
美股大行评级 | 潜在涨幅超50%，数十家机构大幅上调甲骨文目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140203048973164544.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：上调Datavault AI(DVLT)评级至"买入"，目标价3美元</p> <p>• 蒙特利尔银行：维持DoubleVerify Holdings(DV)"跑赢大市"评级，目标价从25美元升至26
06-13 09:33
美股大行评级 | GitLab遭多家大行下调目标价！Stifel首予优步"买入"评级，目标价110美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139839943846023169.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Loop Capital：维持Dave & Buster's Enter(PLAY)"买入"评级，目标价从35美元升至46美元</p> <p>• Stifel：维持嘉年华(CCL)"买入"评级，目标价从31美元升至
06-12 09:46
Expert Outlook: iRhythm Technologies Through The Eyes Of 6 Analysts
In the last three months, 6 analysts have published ratings on iRhythm Technolo...
06-12 03:01
Morgan Stanley Maintains Overweight on iRhythm Technologies, Raises Price Target to $160
Morgan Stanley analyst Cecilia Furlong maintains iRhythm Technologies (NASDAQ:IRTC) with a Overweight and raises the price target from $130 to $160.
06-12 02:17
美股大行评级 | 潜在涨幅112.77%！Craig-Hallum上调PLAYSTUDIOS目标价至3美元，评级升至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1132955525493317632.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Craig-Hallum：上调PLAYSTUDIOS(MYPS)评级至"买入"，目标价从2美元升至3美元</p> <p>• Leerink Partners：上调Fulcrum Therapeutics(FULC)评级至"
05-24 08:40
